RT Journal Article
T1 UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation.
A1 Santos, N
A1 Rodríguez-Romanos, R
A1 Nieto, J B
A1 Buño, I
A1 Vallejo, C
A1 Jiménez-Velasco, A
A1 Brunet, S
A1 Buces, E
A1 López-Jiménez, J
A1 González, M
A1 Ferrá, C
A1 Sampol, A
A1 de la Cámara, R
A1 Martínez, C
A1 Gallardo, D
A1 GvHD/Immunotherapy Working Party of the Spanish Group of Hematopoietic Transplant (GETH), 
AB Minor histocompatibility Ags (mHags) have been implicated in the pathogenesis of GVHD after allogeneic hematopoietic stem cell transplantation (HSCT). Uridine diphospho-glucuronosyltransferase 2B17 (UGT2B17) gene deletion may act as a mHag and its association with acute GVHD (aGVHD) has been described. We retrospectively studied the clinical impact of a UGT2B17 mismatch in a cohort of 1127 patients receiving a HSCT from an HLA-identical sibling donor. UGT2B17 mismatch was present in 69 cases (6.1%). Incidence of severe aGVHD was higher in the UGT2B17 mismatched pairs (22.7% vs 14.6%), but this difference was not statistically significant (P: 0.098). We did not detect differences in chronic GVHD, overall survival, relapse-free survival, transplant-related mortality or relapse. Nevertheless, when we analyzed only those patients receiving grafts from a male donor (616 cases), aGVHD was significantly higher in the UGT2B17 mismatched group (25.1% vs 12.8%; P: 0.005) and this association was confirmed by the multivariate analysis (P: 0.043; hazard ratio: 2.16, 95% confidence interval: 1.03-4.57). Overall survival was worse for patients mismatched for UGT2B17 (P: 0.005). We conclude that UGT2B17 mismatch has a negative clinical impact in allogeneic HSCT from HLA-identical sibling donors only when a male donor is used. These results should be confirmed by other studies.
YR 2015
FD 2015-09-14
LK http://hdl.handle.net/10668/10238
UL http://hdl.handle.net/10668/10238
LA en
DS RISalud
RD Apr 8, 2025